[ad_1]
Yousif Capital Management LLC reduced its stake in Exelixis, Inc. (NASDAQ:EXEL – Get a rating) by 8.4% in the third quarter, according to its latest filing with the SEC. The institutional investor owned 165,031 shares of the biotech company after selling 15,076 shares during the period. Yousif Capital Management LLC owned 0.05% of Exelixis worth $2,588,000 when it last filed with the SEC.
→ Is this the end of capitalism? (From Porter & Company)
Other institutional investors also bought and sold shares of the company. Total Clarity Wealth Management Inc. acquired a new stake in Exelixis in Q2 valued at $36,000. Covestor Ltd increased its position in Exelixis shares by 245.6% during the first quarter. Covestor Ltd now owns 1,676 shares of the biotech company valued at $38,000 after buying an additional 1,191 shares last quarter. Wipfli Financial Advisors LLC bought a new position in shares of Exelixis during the third quarter worth approximately $46,000. China Universal Asset Management Co.Ltd. bought a new position in shares of Exelixis during the third quarter, valued at approximately $47,000. Finally, First Horizon Advisors Inc. increased its position in Exelixis shares by 296.7% during the second quarter. First Horizon Advisors Inc. now owns 2,440 shares of the biotech company valued at $50,000 after buying an additional 1,825 shares last quarter. Hedge funds and other institutional investors own 84.74% of the company’s shares.
Analyst upgrades and downgrades
A number of research analysts have weighed in on the company recently. Morgan Stanley cut its price target on Exelixis from $23.00 to $22.00 and set an “equal weight” rating for the company in a Wednesday, November 2 research report. EF Hutton Acquisition Co. I reduced its price target on Exelixis from $28.00 to $24.00 and set a “buy” rating for the company in a research report on Wednesday January 11th. Truist Financial reduced its price target on Exelixis from $35.00 to $32.00 in a Friday, Dec. 9 research report. Cowen lowered his price target on Exelixis shares from $21.00 to $20.00 in a Monday, Jan. 9 report. Finally, Credit Suisse Group launched a hedge on Exelixis shares in a report on Thursday. They issued an “outperform” rating and a price target of $29.00 for the company. One analyst rated the stock with a hold rating and nine rated the company’s stock with a buy rating. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $27.58.
Exelixis price performance
Shares of NASDAQ EXEL opened at $17.47 on Monday. The company has a market capitalization of $5.64 billion, a P/E ratio of 18.39, a PEG ratio of 0.58 and a beta of 0.69. Exelixis, Inc. has a 1-year low of $14.87 and a 1-year high of $23.40. The company has a 50-day simple moving average of $16.51 and a two-hundred-day simple moving average of $17.45.
Exelixis (NASDAQ:EXEL – Get a rating) last reported quarterly earnings data on Tuesday, November 1. The biotech company reported earnings per share (EPS) of $0.23 for the quarter, beating the consensus estimate of $0.18 by $0.05. The company posted revenue of $411.74 million in the quarter, versus a consensus estimate of $404.15 million. Exelixis achieved a net margin of 18.78% and a return on equity of 13.11%. As a group, equity research analysts expect Exelixis, Inc. to post EPS of 0.53 for the current year.
Insider activity
In other news, EVP Peter Lamb sold 20,000 Exelixis shares in a transaction that took place on Thursday, December 15. The shares were sold at an average price of $15.88, for a total transaction of $317,600.00. Following the completion of the sale, the executive vice president now owns 410,958 shares of the company, valued at $6,526,013.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, accessible via this hyperlink. In other news, director George Poste sold 40,000 shares of Exelixis in a deal that took place on Tuesday, November 29. The shares were sold at an average price of $16.68, for a total transaction of $667,200.00. Following the completion of the sale, the director now owns 193,189 shares of the company, valued at $3,222,392.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, accessible via this hyperlink. Also, VPE Peter Lamb sold 20,000 Exelixis shares in a transaction that took place on Thursday, December 15. The shares were sold at an average price of $15.88, for a total transaction of $317,600.00. Following the transaction, the executive vice president now directly owns 410,958 shares of the company, valued at $6,526,013.04. Disclosure of this sale can be found here. Insiders hold 2.90% of the shares of the company.
Profile Exelixis
Exelixis, Inc is a biopharmaceutical company dedicated to the development, commercialization and discovery of novel drugs for the treatment of cancer. It offers products under the COMETRIQ, CABOMETYX, COTELLIC and MINNEBRO brands. The company was founded by Corey S. Goodman and Stelios B.
Featured articles
Want to see which other hedge funds hold EXEL? Visit HoldingsChannel.com for the latest 13F filings and insider trading for Exelixis, Inc. (NASDAQ:EXEL – Get a rating).
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected].
Before you consider Exelixis, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market spreads… and Exelixis was not on the list.
Although Exelixis currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
.
[ad_2]
news.google.com